We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
- Authors
Cizkova, Magdalena; Susini, Aurélie; Vacher, Sophie; Cizeron-Clairac, Géraldine; Andrieu, Catherine; Driouch, Keltouma; Fourme, Emmanuelle; Lidereau, Rosette; Bièche, Ivan
- Abstract
<bold>Introduction: </bold>PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial.<bold>Methods: </bold>We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years).<bold>Results: </bold>PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ERα] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2- subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup.<bold>Conclusions: </bold>This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.
- Subjects
BREAST cancer research; GENETIC mutation; BREAST cancer patients; TUMOR markers; BREAST cancer treatment; BIOMARKERS
- Publication
Breast Cancer Research, 2012, Vol 14, Issue 1, pR28
- ISSN
1465-5411
- Publication type
journal article
- DOI
10.1186/bcr3113